Zepbound Gets a Price Cut: What This Means for You

Eli Lilly has made a big move to make its weight-loss drug, Zepbound, more affordable. They've lowered the price of single-dose vials, hoping more people can get their hands on it. Now, the starting dose is $299 a month, down from $349. Higher doses are also cheaper now, with the 5 mg dose at $399 and the highest dose at $449. This isn't the first time Lilly has cut prices. They did something similar for their multi-dose pens last month. But those pens are still waiting for the green light from the FDA. Why the price cuts? Well, obesity drugs are in high demand. Lilly's stock has been on a roll, up more than 39% this year. Their drug, tirzepatide, is doing so well it's now the world's best-selling drug. It's marketed as Zepbound for weight loss and Mounjaro for diabetes. But it's not all about profits. Lilly says too many people can't afford these treatments. They've even struck a deal with the Trump administration to lower prices for Medicare, Medicaid, and cash payers. So, what's the catch? Well, Zepbound is approved for adults with obesity or overweight conditions. It's also approved for those with obstructive sleep apnea. But with demand so high, will the price cuts be enough to make it accessible to everyone who needs it?